March 1, 2010
ProMetic Life Sciences Inc. closes US$13,000,000 loan and equity financing
On February 11, 2010, ProMetic announced the closing of a financing deal with U.S.-based Abraxis BioScience for a total of US$13,000,000. In the context of this transaction, ProMetic was represented by a team from BCF LLP comprised of Pascal de Guise and Adam Allouba.

February 6, 2009
Louis-Paul Marin's Article on the Publicizing of Medical Devices
This article was featured in the winter issue on the Medical technology Watch in Canada. Louis-Paul Marin gives an overview of the demands laid out in the Food and Drug Act as well as those of the Medical Devices Regulations.

September 10, 2008
Abraxis and Prometic Enter License Agreements for up to $295 M US for Four Biopharmaceuticals
Abraxis BioScience, Inc. and ProMetic Life Sciences Inc. announced today that they have signed definitive agreements for the development and commercialization, on a world-wide basis (excluding China and Taiwan), of four biopharmaceutical products targeting underserved medical conditions. The transaction includes an initial strategic investment, by Abraxis, in ProMetic of $7 M US at $0.47 CDN per share as well as providing Abraxis rights to make optional investments of up to $25 M US. During this transaction, Prometic was represented by a team from BCF comprised of Pascal de Guide and Adam Allouba. [PDF]